TRUMP Denies Firing — Who’s Lying?

May 10, 2026

Multiple White House sources say President Trump signed off on firing his own Food and Drug Administration chief — but Trump himself says he knows nothing about it.

Story Snapshot

The Wall Street Journal and Reuters reported on May 8, 2026, that Trump approved a plan to remove Food and Drug Administration (FDA) Commissioner Marty Makary.
Trump flatly denied the reports, telling reporters outside the White House, “I know nothing about it.”
Policy clashes over flavored vaping products, abortion pill reviews, and pharmaceutical industry complaints are cited as the driving friction behind the reported ouster.
The White House declined to confirm the reports, and two sources described the decision as “not final,” leaving Makary’s fate unresolved.

What the Reports Actually Say

The Wall Street Journal broke the story on May 8, 2026, reporting that Trump had signed off on a plan to remove Food and Drug Administration (FDA) Commissioner Marty Makary. Reuters independently confirmed the account, citing multiple sources familiar with the matter. Two of those sources, described as White House advisers, said the decision was not final and could still be reversed. A third source close to the White House stated that Makary “is done” and that “Trump signed off.” The White House declined to confirm the reports, saying only that the president had assembled the most experienced administration in history.

Trump’s on-camera denial was direct but brief. Asked by reporters about the reports, he said simply, “I know nothing about it.” That statement, while unambiguous, does not address the specific claims made by named advisers in the Reuters and Wall Street Journal accounts — including the assertion that Trump personally approved the removal plan. The gap between the president’s denial and the sourcing behind the original reports leaves the situation genuinely unresolved.

Policy Clashes Driving the Tension

The reported friction between Trump and Makary centers on several specific policy disagreements. According to multiple outlets, Trump grew frustrated after the FDA approved flavored vaping products — including blueberry and mango varieties — in a move that contradicted his public pledge to “save vaping.” Makary had also faced pressure over delays in reviewing the abortion pill mifepristone and drew complaints from pharmaceutical companies unhappy with the FDA’s pace on drug approvals. Tensions with the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. added further strain.

These documented frictions make the firing rationale plausible regardless of whether Trump personally approved a removal plan. The FDA under Makary has been pulled in competing directions — pressured by the White House on vaping, scrutinized by health reform advocates, and caught between pharmaceutical industry interests and public health mandates. That institutional turbulence is real and well-documented, even if the specific question of Trump’s approval remains contested.

Why the Conflicting Accounts Matter

Stories like this one follow a recurring pattern in Washington: anonymous leaks about imminent high-level firings, followed by presidential denials, with outcomes that range from swift dismissals to quiet reversals. The qualified language in the original reporting — “not final,” “could change” — is a hallmark of leak-driven political journalism, where insiders float trial balloons or signal internal battles rather than announce settled decisions. That context doesn’t make the reports false, but it does mean readers should weigh them carefully.

President Trump reportedly signs off on firing FDA Commissioner Marty Makary – https://t.co/dMxXTyE5uw

— MIKE LEACH (@michaelaleach) May 8, 2026

What makes this story worth watching goes beyond one commissioner’s job security. The FDA oversees drug approvals, food safety, medical devices, and public health policy affecting every American. When anonymous White House sources and the president himself give directly contradictory accounts of a major personnel decision, it raises legitimate questions about how consequential choices are being made — and who is actually in charge of them. Whether Makary stays or goes, the instability itself has real consequences for an agency that millions of people depend on every day.